Inovio announces acceptance of abstract for oral presentation on ino-3107 for the treatment of recurrent respiratory papillomatosis at cosm 2023

Safety and immunological data from both cohorts of the recently completed phase 1/2 trial will be presented on may 5 th plymouth meeting, pa. , april 27, 2023 /prnewswire/ -- inovio (nasdaq: ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-associated diseases, cancer, and infectious diseases, today announced that an abstract has been accepted for oral presentation on ino-3107 for the treatment of recurrent respiratory papillomatosis (rrp) at this year's american broncho-esophagological association (abea) program at the combined otolaryngology spring meetings (cosm) in boston, massachusetts.
INO Ratings Summary
INO Quant Ranking